The Wyoming-incorporated tech firm confirms prioritizing Ethereum over Bitcoin treasury, citing ETH potential as a financial instrument. 

In a Wednesday statement, BioNexus Gene Lab Corporation confirmed the formal approval to establish an Ethereum-focused treasury. The decision makes it the first Nasdaq-listed entity to prioritize ETH as its strategic asset exclusively. 

BioNexus Adopts Ethereum Treasury 

The Wyoming-based tech firm issued the Ethereum Strategy Whitepaper alongside the March 5 announcement outlining the rationale of prioritizing ETH over the common Bitcoin treasury. The firm noted that though Bitcoin offers a strong store of value, Ethereum yields broader utility given its programmable financial platform. 

BioNexus hailed Ethereum, given its yield-generation capabilities to holders via staking, as a core advantage over Bitcoin. Nonetheless, the tech firm recognized the increased adoption by institutional investors in 2024. 

Unlike BTC, the Whitepaper highlights that ETH offers an additional earning stream via staking. Notably, the proof-of-stake (POS) mechanism facilitates

Keep reading this article on E-cryptonews.com.

Leave a Reply